임상 검사 매칭 소프트웨어 시장 규모, 점유율, 동향 분석 보고서 : 전개 모드별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Clinical Trials Matching Software Market Size, Share & Trends Analysis Report By Deployment Mode, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

임상 검사 매칭 소프트웨어 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 임상 검사 매칭 소프트웨어 시장 규모는 2030년까지 3억 9,613만 달러에 이를 것으로 예측됩니다.

2025-2030년의 CAGR은 13.45%를 나타낼 전망입니다. 그리고 의료 부문에서 가상 검사 및 자동화에 대한 수요가 증가하고 있는 것도 시장 성장에 기여하는 주요 요인 중 하나입니다.

임상 검사는 환자의 모집과 일치에 시간이 걸리고 적절한 일치를 찾는 데 어려움을 겪을 수 있습니다. 자격을 갖춘 예비 응답자를 선별하거나 찾는 것, 임상시험의 모든 요소를 고려하고 인식을 확인하며 사전 동의를 얻는 것은 환자를 모집할 때 고려해야 할 요소입니다. 자격 요건에 따라 개인을 채용하는 것이 매우 중요하며, 따라서 COVID-19 시나리오에서는 평가판 매칭 기술이 유용하다는 것이 입증되었습니다.

이 소프트웨어는 적절한 매칭을 찾는 것뿐만 아니라 연구 개발 관련 비용 절감에도 도움이 되며, 사람 손을 통하지 않고 원활한 운영을 가능하게 하고 있습니다.

임상 검사 매칭 소프트웨어 시장 보고서 하이라이트

• 배포 모드별로 웹 및 클라우드 기반 부문이 2024년 수익으로 시장을 독점하고 예측 기간 동안 가장 빠른 CAGR을 나타낼 것으로 예측됩니다. 클라우드 컴퓨팅 모델은 유지보수 및 유지비가 필요하지 않으며 고객은 사용한 서비스에 대해서만 요금을 지불합니다. 반면에 On-Premise 배포에는 사내 인프라, 사내 IT 지원, 운전 자금 및 높은 통합 비용이 소요됩니다. 따라서 웹과 클라우드 기반 모델을 선호합니다.
• 최종 용도별로 제약 기업과 생명 공학 기업이 2024년 최대 수익 점유율을 획득했습니다.
• 계약 연구 기관(CRO) 부문은 예측 기간 동안 가장 빠른 CAGR을 나타낼 것으로 예측됩니다. CRO는 임상 검사에 필요한 전문적 지원, 전문 지식 및 실시 경험을 신속하게 제공하기 때문에 스폰서가 전임 인력을 고용할 필요가 없습니다. CRO의 서비스는 비용 효과적이고 시간대 효과가 높기 때문에 아웃소싱 목적지로 선호됩니다.
• 이 지역의 제약, 바이오테크놀러지, 의료 관련 기업에 의한 임상 검사 매칭 소프트웨어의 채용이 증가하고 있기 때문에 2024년에는 북미가 기업 수익으로 시장을 선도하게 됩니다.
• 아시아태평양은 환자, 후보자의 간편한 모집을 지원하는 대규모 환자 풀을 사용할 수 있으므로 예측 기간 동안 가장 빠른 성장률을 나타낼 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 임상검사 매칭 소프트웨어 시장의 변수, 동향, 범위

• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회 분석
• 임상 검사 매칭 소프트웨어 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 신흥기술
  • 이용 사례와 통찰
  • COVID-19의 영향 분석

제4장 임상 검사 매칭 소프트웨어 시장 : 전개 모드, 추정 및 예측 분석

• 전개 모드 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 전개 모드별 세계의 임상 검사 매칭 소프트웨어 시장 전망
• 웹과 클라우드 기반
• On-Premise

제5장 임상 검사 매칭 소프트웨어 시장 : 최종 용도별, 추정 및 예측 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 최종 용도별 임상 검사 매칭 소프트웨어 시장 전망
• 제약 및 바이오테크놀러지 기업
• CRO
• 의료기기 기업

제6장 임상 검사 매칭 소프트웨어 시장 : 지역 추정 및 예측 분석, 전개 모드별, 최종 용도별

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업, 경쟁의 분류
• 주요 기업의 시장 점유율/위치 분석, 2024년
• 기업 프로파일
  • IBM
  • Antidote Technologies, Inc.
  • RealTime Software Solutions, LLC
  • Optimapharm.
  • Advarra
  • BSI Business Systems Integration AG
  • Clario
  • HealthMatch
  • Microsoft
  • Deep6.ai
  • Inspirata, Inc.
  • Mendel Health Inc.
  • MatchTrial
  • Curewiki
  • Inteliquet(IQVIA)
  • Tempus Labs

SHW

영문 목차

영문목차

Clinical Trials Matching Software Market Growth & Trends:

The global clinical trials matching software market size is expected to reach USD 396.13 million by 2030, based on a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 13.45% from 2025 to 2030. The significant increase in the number of ongoing clinical trials is likely to drive the market. In addition, the growing adoption of the clinical trial matching software catering to the clinical trials, along with the increased demand for virtual trials and automation in the healthcare sector are some of the key factors contributing to the market growth. The matching software help in effective and fast patient matching with patient-centric approaches.

In clinical trials, patient recruitment or matching can be time-consuming, and finding the right match can be a hurdle. Screening or locating prospective respondents who are qualified, considering all elements of the trials, verifying awareness, and getting informed consent to participate are the factors taken into consideration while recruiting patients. Enlisting the individuals in accordance with the qualifying requirements is crucial, hence the trial matching technology has been proved to be useful, especially in the COVID-19 scenario.

The software helps not only to find the right match but also saves the R&D-related costs, enabling smoother operations without human intervention. The software providers are introducing new innovative techniques to strengthen their market position. For instance, in February 2022, the CTMA expanded CT-SCOUT technology offering in rheumatology.

Clinical Trials Matching Software Market Report Highlights:

• Based on deployment mode, the web and cloud based segment dominated the market in terms of revenue in 2024 and it is expected to register the fastest CAGR during the forecast period. The cloud computing models operate with no maintenance or upkeep charges and customers only have to pay for the services that are used. On the other hand, on-premises deployment involves in-house infrastructure, in-house IT support, working capital, and higher integration costs. Hence, web and cloud based models are preferred
• Based on end use, pharmaceuticals and biotechnology companies captured the largest revenue share in 2024 owing to the higher adoption of software during ongoing clinical studies for cost-saving in the R&D activities
• Contract Research Organizations (CRO) segment is expected to register the fastest CAGR over the forecast period. CROs provide the professional assistance, expertise, and execution experience required for clinical trials quickly, without the need for the sponsor to engage such people full-time. CROs are preferred for outsourcing as their services are cost and time-effective
• In 2024, North America led the market in terms of revenue owing to the rising adoption of the clinical trial matching software by the pharma, biotech, and medical companies in the region
• Asia Pacific is anticipated to register the fastest growth rate over the forecast period due to the availability of a large patient pool supporting easy recruitment of patients/candidates

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Deployment mode
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Deployment mode outlook
  • 2.2.2. End use
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trials Matching Software Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market Driver Analysis
    • 3.1.1.1. Growing Complexity of Clinical Trials
    • 3.1.1.2. Increasing Demand for Precision Medicine & Personalized Trials
    • 3.1.1.3. Regulatory Push for Enhanced Patient Enrollment Efficiency
    • 3.1.1.4. Rising Investments in Digital Health & Clinical Research Technologies
    • 3.1.1.5. Expanding Clinical Trial Pipelines & Decentralized Trials
    • 3.1.1.6. Partnerships Between Pharma Companies & Tech Firms for Advanced Solutions
  • 3.1.2. Market Restraint Analysis
    • 3.1.2.1. High Implementation and Maintenance Costs
    • 3.1.2.2. Data Privacy and Security Concerns
  • 3.1.3. Market Opportunities Analysis
• 3.2. Clinical Trials Matching Software Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape
  • 3.2.3. Emerging Technologies
  • 3.2.4. Case Studies & Insights
  • 3.2.5. COVID-19 Impact Analysis

Chapter 4. Clinical Trials Matching Software Market: Deployment Mode Estimates & Trend Analysis

• 4.1. Deployment Mode Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Clinical Trials Matching Software Market by Deployment Mode Outlook
• 4.4. Web & Cloud-based
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. On-Premises
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Clinical Trials Matching Software Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Clinical Trials Matching Software Market by End Use Outlook
• 5.4. Pharmaceutical & Biotechnology Companies
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. CROs
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Medical Device Companies
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Clinical Trials Matching Software Market: Regional Estimates & Trend Analysis, By Deployment Mode and By End Use

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Key company market share/position analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. IBM
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Technology Type benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Antidote Technologies, Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Technology Type benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. RealTime Software Solutions, LLC
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Technology Type benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Optimapharm.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Technology Type benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Advarra
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Technology Type benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. BSI Business Systems Integration AG
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Technology Type benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Clario
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Technology Type benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. HealthMatch
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Technology Type benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Microsoft
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Technology Type benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Deep6.ai
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Technology Type benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Inspirata, Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Technology Type benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Mendel Health Inc.
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Technology Type benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. MatchTrial
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Technology Type benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Curewiki
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Technology Type benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. Inteliquet (IQVIA)
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Technology Type benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Tempus Labs
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Technology Type benchmarking
    • 7.4.16.4. Strategic initiatives

관련자료